HERON THERAPEUTICS, INC. /DE/
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
HRTX$0.37+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Net product sales | $35,250 | $38,213 | $107,627 | $114,316 |
| Cost of product sales | 8,958 | 11,914 | 31,168 | 30,228 |
| Gross profit | 26,292 | 26,299 | 76,459 | 84,088 |
| Operating expenses: | ||||
| Research and development | 3,099 | 3,470 | 8,186 | 8,683 |
| General and administrative | 12,341 | 13,980 | 35,762 | 41,153 |
| Sales and marketing | 12,521 | 12,942 | 40,989 | 36,828 |
| Total operating expenses | 27,961 | 30,392 | 84,937 | 86,664 |
| Loss from operations | (1,669) | (4,093) | (8,478) | (2,576) |
| Loss on debt extinguishment | — | (11,339) | — | (11,339) |
| Other expense, net | (3,337) | (2,063) | (10,128) | (3,326) |
| Net loss | (5,006) | (17,495) | (18,606) | (17,241) |
| Other comprehensive loss: | ||||
| Unrealized (loss) gain on short-term investments | (1) | 1 | (11) | (13) |
| Comprehensive loss | $(5,007) | $(17,494) | $(18,617) | $(17,254) |
| Basic net loss per share | $(0.03) | $(0.10) | $(0.10) | $(0.11) |
| Diluted net loss per share | $(0.03) | $(0.10) | $(0.10) | $(0.11) |
| Weighted average common shares outstanding, basic and diluted | 190,919 | 170,348 | 190,305 | 159,524 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.